How TrumpRx claims to reduce medication costs and who truly gains from it

New Website Aims to Lower Prescription Drug Prices

The White House has launched a new site called TrumpRx, which is intended to reduce the prices of various prescription drugs significantly. While the administration calls this a historic initiative, experts caution that its reach may be somewhat limited.

Some medications that used to cost over $1,000 per month are now available for a few hundred dollars on TrumpRx.

Currently, the site features 43 branded medications, with discounts that range from 50% to more than 90%.

Notable examples include weight loss and diabetes medications from Novo Nordisk and Eli Lilly, with Wegovy pills and pens discounted by up to 89%, Ozempic pens by 81%, and Zepbound offered at around 72% off.

Insulin lispro is priced starting at $25, which the government has highlighted as a benchmark for affordability.

Included in the offerings are infertility medications from EMD Serono, like Gonal F and Ovidrel, as well as various diabetes drugs such as Farxiga and Sigduo XR, and thyroid medications like Levoxil and Cytomel.

Additionally, TrumpRx features combinations of medications for respiratory issues, autoimmune diseases, hormonal treatments, and mental health.

Many of these drugs are older branded products, and some already have generic options available. This leads experts to believe that the most substantial savings will benefit those who pay out of pocket, rather than the majority of insured Americans.

TrumpRx doesn’t actually sell medications directly.

Instead, it acts as a resource that guides patients to manufacturer discount programs, coupon codes, and pharmacies where they can buy drugs with cash, avoiding insurance altogether.

This payment method typically bypasses deductibles and annual out-of-pocket maximums, which experts believe makes it more suited for uninsured patients or those paying cash.

Darren Covington of the Indiana Pharmacy Association noted mixed reactions from early discussions.

“Some people are really enthusiastic about it, while others are a bit doubtful,” he mentioned.

“We definitely know that when patients can afford their medications, it generally leads to better health outcomes. So there’s hope there,” he added.

However, academic experts in health policy have cautioned that the actual benefits for most Americans may be exaggerated.

Sean Sullivan, a health economics professor at the University of Washington, pointed out that “TrumpRx is tailored for uninsured patients who are paying in cash, which means it won’t help the majority of Americans,” emphasizing that about 85% of people have some form of prescription drug insurance.